DNMT3A and acute myeloid leukemia: Among patients harboring DNMT3A mutations, some had ever been given hypomethylating agents (HMAs), whereas others had never been given HMAs, so we further explored the exact benefit of HMAs in AML patients carrying such types of mutations.